Summary:
The authors examined, using a new method of the ELISA test for assessment of antibodies against
beta2 glycoprotein I (b2-GPI), 142 serum samples from patients with various diffuse connective tissue
diseases. 72 samples were continuously collected from patients with SLE or some clinical or
laboratory manifestations of the antiphospholipid syndrome. Other serum samples came from
a serum bank of an immunological laboratory. Thirty cases of SLE were involved, 20 cases of systemic
scleroderma and 20 cases of polymyositis/dermatomyositis. All sera were also examined for the
presence of anticardiolipin antibodies (aCL). The results of the two methods were compared.
A considerable degree of correlation of results of the two tests was found. However, several different
results indicate that by the test for anti-b2 glycoprotein antibodies other members of the group of
heterogeneous antiphospholipid antibodies can be detected. In particular for establishment of the
diagnosis of antiphospholipid syndrome (APS) it is useful to assess in addition to the lupus
anticoagulans (LA) and anticardiolipin antibodies also antibodies against b2-glycoprotein I.
Key words:
antiphospholipid syndrome, anticardiolipin antibodies, antibodies against beta2-gly-
coprotein I
|